

[View it in your browser](#)



Nephrology Education Portal (NEP) Newsletter

Issue 05 - March 2021

EDITOR IN CHIEF: Davide Bolignano
EDITORIAL BOARD: click [here](#) for the complete list

ERA-EDTA e-seminars Summary Report

CKD patients and their risk of a severe course of COVID-19 - ERACODA e-seminars series



Kidney related aspects of COVID-19
ERACODA e-seminars series

e-seminar #1:
CKD patients and their risk for a severe course of COVID-19
Moderator: **Luuk Hilbrands, NL**

Is CKD the key risk factor for COVID-19 mortality?
Presenter: **Ron Gansevoort, NL**
Panellist: **Alberto Ortiz, ES**

Risk factors for COVID-19 mortality in the CKD population. Are they different from the general population?
Presenter: **Marlies Noordzij, NL**
Panellist: **Cecile Couchoud, F**

Thursday - November 12, 2020
From 5:00 to 6:00 PM CET

www.era-edta.org

The coronavirus COVID-19 pandemic presented an unprecedented challenge to healthcare services worldwide in the previous months. The disease afflicts multiple organ systems and may also target kidney cells and cause acute kidney injury. On the other hand, patients with existing chronic kidney disease (CKD) are at a much higher risk for severe illness when infected. In response to the COVID-19 pandemic the European Renal Association- European Dialysis Transplantation Association (ERA-EDTA) established the European Renal Association COVID-19 Database (ERACODA) in March 2020 to investigate the clinical course, outcomes, and risk factors for mortality in kidney replacement patients with COVID-19.

[Read more](#)

[Watch the Webcast](#)

ERA-EDTA e-seminars Summary Report

All you want to know about COVID-19 vaccination of kidney patients - ERACODA e-seminars series

ERACODA e-seminar #4

All you want to know about COVID-19 vaccination of kidney patients

Round Table

Moderators: **Luuk Hilbrands, NL**
Ron Gansevoort, NL

Panellist:

Marco Cavaleri, IT
Representative European Medicines Agency (Section Vaccines)

Fiona Loud, UK
Patient representative (Policy Director at Kidney Care UK)

Piorgorgio Messa, IT
Expert on vaccination in CKD

Marta Crespo, ES
Expert on vaccination in transplant patients

Marjolein van Egmond, NL
Expert on immunology and vaccination

Thursday - January 7, 2021
From 5:00 to 6:15 PM CET



www.era-edta.org
This independent e-seminar
is supported by Baxter

Since medications to treat COVID-19 are unlikely to be developed soon, effective and safe vaccines and continuous infection mitigation strategies are currently the only realistic options to curb the ongoing pandemic. While vaccination is a powerful and cost-effective method to reduce infection-related morbidity and mortality, vaccine efficacy has historically not been rigorously studied in chronic kidney disease (CKD) patients, and COVID-19 vaccines immunogenicity is largely unknown in this high-risk population.

[Read more](#)

[Watch the Webcast](#)

Further readings:

Kronbichler A, Anders H-J, Fernandez- Juárez GM et al. Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. *Nephrol Dial Transplant* 2021 Mar doi.org/10.1093/ndt/gfab064

Francis A, Baigent C, Ikizler TA, Cockwell P, Jha V. The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. *Kidney Int.* 2021 Apr;99(4):791-793. [doi: 10.1016/j.kint.2021.02.003](https://doi.org/10.1016/j.kint.2021.02.003).

ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. *Nephrol Dial Transplant.* 2021 Jan 1;36(1):87-94. [doi: 10.1093/ndt/gfaa314](https://doi.org/10.1093/ndt/gfaa314). PMID: 33340043; PMCID: PMC7771976.

De Meester J, De Bacquer D, Naesens M, Meijers B, Couttenye MM, De Vriese AS; NBVN Kidney Registry Group. Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study. *J Am Soc Nephrol.* 2021 Feb;32(2):385-396. [doi: 10.1681/ASN.2020060875](https://doi.org/10.1681/ASN.2020060875). Epub 2020 Nov 5. PMID: 33154174.

Follow us



The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA in compliance with the EU General Data Protection Regulation (2016/679).

[Unsubscribe](#)

© 2021 ERA-EDTA